Mostrando 10 resultados de: 14
Filtros aplicados
Área temáticas
Medicina y salud(9)
Farmacología y terapéutica(8)
Enfermedades(4)
Dirección general(2)
Biblioteconomía y Documentación informatica(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(14)
ODS 17: Alianzas para lograr los objetivos(13)
ODS 10: Reducción de las desigualdades(8)
ODS 9: Industria, innovación e infraestructura(3)
ODS 12: Producción y consumo responsables(2)
Origen
scopus(14)
Clinical drug-drug interactions: Focus on venlafaxine
ReviewAbstract: Venlafaxine (VEN) is an antidepressant agent widely used nowadays as an alternative to selective serPalabras claves:Drug-drug interactions, pharmacodynamics, pharmacokinetics, VenlafaxineAutores:Adrián LLerena, Alves G., Falcao A.C., Magalhães P.Fuentes:scopusClinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Mata-Martín C., Penãs-Lledó E.M., Pijierro A., Sánchez C.L.Fuentes:scopusAn update on HLA alleles associated with adverse drug reactions
ReviewAbstract: Adverse drug reactions (ADRs) are considered as an important cause of morbidity and mortality. The hPalabras claves:abacavir, adverse drug reactions, Allopurinol, carbamazepine, human leukocyte antigen (HLA), hypersensitivity syndrome, pharmacogenetics, Stevens-Johnson syndromeAutores:Adrián LLerena, Fricke-Galindo I., López-López M.Fuentes:scopusDrug-drug interactions. Things to do in pain management
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Margargit C., Peiró A.M.Fuentes:scopusInterethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: A report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics)
ReviewAbstract: Mexico presents a complex population diversity integrated by Mexican indigenous (MI) (7% of Mexico'sPalabras claves:drug metabolizing enzymes, drug receptors, drug transporters, Mexicans, pharmacogeneticsAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusThe need of the clinical implementation of pharmacogenetics in European health services for routine drug prescription. What's next? An urgent clinical unmet need for patients
OtherAbstract:Palabras claves:drug prescription, health services, Implementation, pharmacogenetics, Pharmacogenomics, regulationAutores:Adrián LLerena, Manolopoulos V.G., Rodríguez-Antona C., Stanković S., Taron M., Van Schaik R.H.N.Fuentes:scopusNew perspectives in personalised medicine for ethnicity in cancer: Population pharmacogenomics and pharmacometrics
ReviewAbstract:Palabras claves:Autores:Adrián LLerena, Nair S.Fuentes:scopusNews in DMPT: Leaders in Pharmacogenetics Section
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Fricke-Galindo I.Fuentes:scopusMetabolic phenotype prediction from genotyping data: A bottleneck for the implementation of pharmacogenetics in drug development and clinical practice
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Penãs-Lledó E.M.Fuentes:scopusPredictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen
ReviewAbstract: Bevacizumab was the first molecular-targeted antiangiogenic therapy approved for the treatment of mePalabras claves:Bevacizumab, Biomarker, Cáncer, colorectalAutores:Adrián LLerena, Alonso I., Arroyo G., de Andrés F., Estévez-Carrizo F.E., González-Vacarezza N., Martínez J.Fuentes:scopus